BioMedomics

Executive Summary

BioMedomics, a US-based diagnostics company and subsidiary of OraSure Technologies, specializes in developing rapid point-of-care tests for infectious diseases and blood disorders. Its flagship product, Sickle SCAN®, is the world's first rapid POC test for sickle cell disease and trait, addressing a critical need in under-resourced settings. The company focuses on creating affordable, accessible diagnostic solutions for global health, leveraging its expertise in rapid immunoassays to improve disease management and screening in low- and middle-income countries. With sickle cell disease affecting millions worldwide, Sickle SCAN® has the potential to significantly impact screening and diagnosis in regions with limited laboratory infrastructure. As a subsidiary of a larger public company, BioMedomics benefits from OraSure's commercial and regulatory infrastructure while maintaining a focused mission. The company's pipeline likely includes next-generation rapid tests for other neglected tropical diseases or expansion of its sickle cell test into new markets. Key growth drivers include regulatory approvals in high-burden countries, partnerships with global health organizations, and potential WHO prequalification. However, as a private subsidiary, its financial performance and strategic direction are closely tied to OraSure's priorities, which may limit independent catalysts. The conviction score reflects the clear unmet need and established product, offset by dependency on parent company strategy.

Upcoming Catalysts (preview)

• Q2 2026WHO prequalification or expanded regulatory approvals for Sickle SCAN® in key endemic countries65% success
• Q4 2026Launch of a new rapid POC test for an additional infectious disease (e.g., malaria or dengue)40% success
• Q3 2026Strategic partnership with a global health foundation for distribution in Africa50% success